WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology
The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019.
ASCO® endorsed for the past 11 years, the WIN symposium will deliver an
exciting line-up of speakers in Paris (France) on June 23-24, 2019 to
discuss Innovation and Global Deployment of Precision Oncology.
The
current status of Precision Oncology across the globe will be examined
with the exceptional participation of the chairmen of the event, Richard
L. Schilsky, Chairman WIN Consortium(*), Senior
Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero,
Vice Chairman WIN Consortium, President of ESMO and Director of Vall
d’Hebron Institute of Oncology, Spain.
Global experience will be shared:
- Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA
- Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA
- The Value of Personalized Medicines for Healthcare Systems in Europe – by the European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Rapidly changing landscape of Precision Medicine in Japan, Tokyo Medical and Dental University
- National Cancer Grid of India – Earthshots over Moonshots, TATA Memorial Hospital
- Development and Application of Precision Oncology in China, Fudan University Shanghai Cancer Center
World leading precision oncologists will deliver breakthrough science, including:
- Prof. Jennifer A. Doudna, PhD, University of California, Berkeley, USA “Rewriting the Code of Life: CRISPR-Cas Genome Editing”.
- Dr. Jennifer A. Ligibel, MD, Harvard Medical School and Dana Farber Cancer Institute, USA “Lifestyle-based Prevention Strategies”.
- Dr. Razelle Kurzrock, MD, University of California, San Diego, USA, “Innovation in Clinical Trials: WINTHER trial”, first study pioneered by the WIN Consortium (*), that showed that assessing RNA is an important adjunct to DNA profiling for determining treatments and rings in a new era for personalized medicine in oncology. WINTHER results were recently published in Nature Medicine (**)
- Prof. Christophe Le Tourneau, MD., PhD, Institut Curie, France, “Innovative Ways of Assessing Durable Response under Immunotherapy”
- Dr. Jean François Martini, PhD., MSc, Pfizer Inc., “Addressing Mechanisms of Resistance Following Anti-Cancer Therapy: a Pharma Perspective”
- Prof. Angel Porgador, PhD, Ben Gurion University of Negev, Israel, “Efficient In Vitro Screening for Drug Combinations: The TEVA Model”
Do not miss the two microsatellites hosted at the WIN Symposium:
- Real-World Evidence and its Relevance for Clinical Practice and Stakeholder Decision Making - F. Hoffmann-La Roche Ltd
- Artificial Intelligence to Support Patient Profiling in Precision Oncology - Definiens AG
The WIN symposium provides outstanding networking opportunities for all professionals in cancer care.
(*) WIN Consortium is a non-profit organization based in Paris, France. We are a worldwide network assembling cancer stakeholders from four continents to develop cutting edge concepts and clinical trials that improve survival for cancer patients. WIN members include 28 outstanding cancer centers plus 11 additional leading pharmaceutical, technology companies and patient advocacy organizations representing stakeholders in precision cancer medicine, www.winconsortium.org
(**) Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial https://doi.org/10.1038/s41591-019-0424-4
For more information: www.winsymposium.org
ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190517005150/en/
Contact information
WIN Consortium
Vladimir Lazar
Chief Scientific and Operating
Officer
vladimir.lazar@winconsortium.org
Telephone:
+ 33 66 109 15 22
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo